Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease

NCT ID: NCT04524377

Last Updated: 2020-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-25

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The intention of the study is to investigate whether Deep Brain Stimulation (DBS) will improve postural deformities of patients with Parkinson's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Introduction

Postural deformities are frequent comorbidities that limit the quality of life in patients with Parkinson's disease. Subject of the study is the investigation of postural deformities as a concomitant disease in connection with therapy with DBS. The aim of this prospective study is to examine the effect of deep brain stimulation on postural instability and thus the quality of life of patients.
2. Study outline

The aim of this prospective study is to investigate the effect of DBS on postural instability and thus the quality of life of patients.

For this purpose, the investigators would like to evaluate 50 participants before and at certain time points (three, six, twelve and 24 months) after DBS surgery. X-rays of the entire spine are carried out using EOS® technology and biodynamic measurements of the spine using the Epionics SPINE ® system. In addition, the Investigators collect the 39-item PD Questionnaires (PDQ-39), Unified Parkinson's Disease Rating Scale (UPDRS) Part III, Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) as clinical parameters.

Our hypotheses (I): DBS improves the sagittal balance of the spine and the pelvic rotation as a corresponding compensation mechanism for this incorrect posture (II) The participant's mobility improves in course of DBS in terms of scope and speed (III) In course after DBS, back pain is significantly reduced and the participant's everyday life is easier to cope with.

The investigators hope to gain new insights into the pathophysiology of the spinal deformities associated with Parkinson's disease from the study and to expand the indication for DBS to include clinically relevant spinal complaints.
3. Consent to the study

The study was positively assessed by the Charité ethics committee and the Federal Office for Radiation Protection.

Consent for study inclusion is sought after explanation and agreement to DBS treatment for participants with Parkinson's disease. Thus, participants capable of consenting to the DBS treatment get the study details explained themselves and may or may not agree to participate. If a participant is incapable for consenting to the proposed treatment, he may not be enrolled in the study.
4. Safety of DBS for Parkinson's disease and further risks for participants

Deep brain stimulation is a well-established and well-tolerated treatment for Parkinson's disease.

The study-related risks result from the multiple X-ray examinations of the spine (effective dose 2.6 µSv per examination). There are no other study-related risks of the planned ones.
5. Insurance Coverage

An insurance was taken out for all study participants who took part in this study at HDI-Gerling Industrie Versichung AG, Riethorst 2, 30659 Hanover, Insurance number: 5701032603017.

German laws §§ 40 to 42 Arzneimittelgesetz or §§ 20 to 23 Medizinproduktegesetz are not applicable.

The Investigators are insured against fault-based damage through the existing liability insurance of their clinic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Spine Degeneration Spine Deformity Spinal Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Deep Brain Stimulation Parkinson Disease Spine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Deep Brain Stimulation (DBS) of the Nucelus subthalamicus (STN) in patients with Parkinson's Disease (PD).
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

The Radiologist who evaluated X-rays ist masked regarding timepoint of investigation

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DBS for Parkinsons Disease

Group Type EXPERIMENTAL

Deep Brain Stimulation

Intervention Type PROCEDURE

Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.

The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep Brain Stimulation

Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.

The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women and men, over 18 years of age
* medical indication for deep brain Stimulation for Parkinson's Disease
* signed declaration of consent

Exclusion Criteria

* withdrawal of consent
* non-Parkinson's-associated diseases of the spine
* pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Charite University, Berlin, Germany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Philipp Spindler

Dr. med. Philipp Spindler, Resident, Principal Investigator, Charite University medicine / department of neurosurgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philipp Spindler

Role: PRINCIPAL_INVESTIGATOR

Charite University, Berlin, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charité University Medicine Department of Neurosurgery Campus Charité Mitte

Berlin, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Philipp Spindler

Role: CONTACT

Phone: +49(0)30450660778

Email: [email protected]

Katharina Faust

Role: CONTACT

Phone: +49(0)30450660178

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Philipp Spindler

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

40000256

Identifier Type: -

Identifier Source: org_study_id